The lawsuit, filed in the United States District Court for the District of Massachusetts, covers the period between February 21, 2025, and May 26, 2026. Plaintiffs allege that top leadership, including current CEO Ashley A. McEvoy and CFO Flavia H. Pease, along with former executives James R. Hollingshead, Ana M. Chadwick, Eric Benjamin, and Chief Medical Officer Trang Ly, made materially false statements about the production standards of the Omnipod system. The complaint centers on the assertion that these officers personally certified SEC filings while aware of systemic manufacturing defects at the company's Acton facility.
Insulet Executives Named in Securities Class Action Over Manufacturing Flaws
Investors in Insulet Corporation are facing significant losses following a drop in share price from $236.07 to $146.01, triggered by two medical device corrections. A securities class action lawsuit now targets six senior executives for allegedly misleading shareholders regarding the company's manufacturing quality and safety controls.
According to the allegations, the defendants utilized their authority to suppress information regarding quality control failures while simultaneously touting the company's manufacturing efficiency to analysts and investors. The legal action leverages Section 20(a) of the Securities Exchange Act, arguing that these executives failed in their Sarbanes-Oxley obligations to ensure the accuracy of financial and operational disclosures. Court records indicate that three of the named defendants sold over 21,180 shares for roughly $5.9 million during the period in question. The deadline for investors to apply for lead plaintiff appointment is August 31, 2026.
Comments (0)
No comments yet. Be the first!